{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:03:21Z","timestamp":1761746601101,"version":"build-2065373602"},"reference-count":24,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,1,25]],"date-time":"2013-01-25T00:00:00Z","timestamp":1359072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2013,8]]},"abstract":"<jats:sec>\n                    <jats:title>What's known on the subject? and What does the study add?<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            <jats:styled-content style=\"fixed-case\">UroVysion<\/jats:styled-content>\n                            \u2122 is a multicolour fluorescence\n                            <jats:italic>in situ<\/jats:italic>\n                            hybridisation assay that detects\n                            <jats:styled-content style=\"fixed-case\">DNA<\/jats:styled-content>\n                            gain at chromosomes 3, 7 and 17 and loss at the 9p21 locus in exfoliated urothelial cells. This cell\u2010based test is time\u2010consuming and costly compared with voided urine cytology or other molecular markers for the early detection of bladder cancer.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            We determined copy number changes at chromosomes 3, 7 and 17 and at the 9p21 locus with UroVysion in a prospective screening study among chemical workers. Strong correlations between\n                            <jats:styled-content style=\"fixed-case\">DNA<\/jats:styled-content>\n                            gains yield a similar performance in detecting bladder cancer with just one of the probes for chromosomes 3, 7 or 17 instead of all, supporting the development of a simpler and cheaper assay.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>To explore changes at chromosomes 3, 7, 17 and 9p21 in order to assess associations with bladder cancer for possible improvements of the UroVysion\u2122 assay regarding screening.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Subjects and Methods<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            In all, 1609 men took part in the prospective study\n                            <jats:styled-content style=\"fixed-case\">UroScreen<\/jats:styled-content>\n                            . Annual screening for bladder cancer was offered to male chemical workers with former exposure to aromatic amines as a voluntary surveillance programme between 2003 and 2010.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            In all, 191\u2009434 cells in 6517\n                            <jats:styled-content style=\"fixed-case\">UroVysion<\/jats:styled-content>\n                            tests were analysed for copy number variations (\n                            <jats:styled-content style=\"fixed-case\">CNV<\/jats:styled-content>\n                            ) at chromosome 3, 7, 17 (gains) and 9p21 (deletions) in 1595 men.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            We assessed\n                            <jats:styled-content style=\"fixed-case\">CNVs<\/jats:styled-content>\n                            at single or multiple loci using polysomy indices (\n                            <jats:styled-content style=\"fixed-case\">PIs<\/jats:styled-content>\n                            , called multiple\n                            <jats:styled-content style=\"fixed-case\">PI<\/jats:styled-content>\n                            and\n                            <jats:styled-content style=\"fixed-case\">PI<\/jats:styled-content>\n                            3,\n                            <jats:styled-content style=\"fixed-case\">PI<\/jats:styled-content>\n                            7 and\n                            <jats:styled-content style=\"fixed-case\">PI<\/jats:styled-content>\n                            17).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            We calculated Spearman's rank correlation coefficients (r\n                            <jats:sub>s<\/jats:sub>\n                            ) between these\n                            <jats:styled-content style=\"fixed-case\">PIs<\/jats:styled-content>\n                            and receiver operating characteristic (\n                            <jats:styled-content style=\"fixed-case\">ROC<\/jats:styled-content>\n                            ) curves with areas under the curves (\n                            <jats:styled-content style=\"fixed-case\">AUCs<\/jats:styled-content>\n                            ). We applied Cox regression to estimate hazard ratios (\n                            <jats:styled-content style=\"fixed-case\">HRs<\/jats:styled-content>\n                            ) to assess the risk of developing bladder cancer.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Nine out of 21 bladder tumours detected in 20 participants (\u2018cases\u2019) had a positive UroVysion test, including seven high\u2010grade carcinomas and seven overlapping results with a positive cytology. Four cases with negative test results did not attend screening annually.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>No case was found because of a complete loss of 9p21 in at least 12 cells.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            There were strong correlations between pairwise combinations of gains at chromosome 3, 7 or 17, ranging between r\n                            <jats:sub>s<\/jats:sub>\n                            = 0.98 and r\n                            <jats:sub>s<\/jats:sub>\n                            = 0.99 in cases and between r\n                            <jats:sub>s<\/jats:sub>\n                            = 0.84 and r\n                            <jats:sub>s<\/jats:sub>\n                            = 0.88 in non\u2010cases (\n                            <jats:italic>P<\/jats:italic>\n                            &lt; 0.001). Associations were less pronounced with\n                            <jats:styled-content style=\"fixed-case\">CNVs<\/jats:styled-content>\n                            at 9p21 among cases and were lacking in non\u2010cases.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Estimates of the relative risk of\n                            <jats:styled-content style=\"fixed-case\">DNA<\/jats:styled-content>\n                            gain for developing a bladder tumour assessed with\n                            <jats:styled-content style=\"fixed-case\">PIs<\/jats:styled-content>\n                            (threshold 10% of cells) were 47.7 (95% confidence interval [\n                            <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                            ] 18.3\u2013124.1) for the multiple\n                            <jats:styled-content style=\"fixed-case\">PI<\/jats:styled-content>\n                            , 44.5 (95%\n                            <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                            16.5\u2013119.9) for\n                            <jats:styled-content style=\"fixed-case\">PI<\/jats:styled-content>\n                            3, 34.7 (95%\n                            <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                            13.1\u201392.1) for\n                            <jats:styled-content style=\"fixed-case\">PI<\/jats:styled-content>\n                            7 and 52.4 (95%\n                            <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                            20.7\u2013132.6) for\n                            <jats:styled-content style=\"fixed-case\">PI<\/jats:styled-content>\n                            17, as well as 7.9 (95%\n                            <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                            3.0\u201320.6) for a complete loss of 9p21 (threshold 2.5% of cells), respectively.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            <jats:styled-content style=\"fixed-case\">ROC<\/jats:styled-content>\n                            analyses showed similar\n                            <jats:styled-content style=\"fixed-case\">AUCs<\/jats:styled-content>\n                            for multiple\n                            <jats:styled-content style=\"fixed-case\">PI<\/jats:styled-content>\n                            compared with\n                            <jats:styled-content style=\"fixed-case\">PIs<\/jats:styled-content>\n                            of single chromosomes 3, 7 and 17 (all\n                            <jats:styled-content style=\"fixed-case\">AUCs<\/jats:styled-content>\n                            between 0.79 and 0.80) and a lower\n                            <jats:styled-content style=\"fixed-case\">AUC<\/jats:styled-content>\n                            for a homozygous loss of 9p21 (\n                            <jats:styled-content style=\"fixed-case\">AUC<\/jats:styled-content>\n                            0.72).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>The UroVysion assay showed a reasonable performance in detecting bladder cancer in the present study population and shared positive test results with cytology, which is much cheaper.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            A simpler, faster and cheaper version of the UroVysion assay might rely on the very strong correlations between gains at chromosomes 3, 7 and 17, resulting in a similar performance in detecting bladder cancer with single\u2010probe\n                            <jats:styled-content style=\"fixed-case\">PIs<\/jats:styled-content>\n                            compared with the full set of these probes.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Loss of 9p21 was less predictive for developing bladder cancer in\n                            <jats:styled-content style=\"fixed-case\">UroScreen<\/jats:styled-content>\n                            .\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2012.11666.x","type":"journal-article","created":{"date-parts":[[2013,1,25]],"date-time":"2013-01-25T12:15:08Z","timestamp":1359116108000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Chromosomal instability and bladder cancer: the\n                    <scp>UroVysion<\/scp>\n                    <sup>TM<\/sup>\n                    test in the\n                    <scp>UroScreen<\/scp>\n                    study"],"prefix":"10.1111","volume":"112","author":[{"given":"Nadine","family":"Bonberg","sequence":"first","affiliation":[{"name":"Institute for Prevention and Occupational Medicine of the German Social Accident Insurance Institute of the Ruhr\u2010Universit\u00e4t Bochum (IPA)  Bochum Germany"},{"name":"Protein Research Unit Ruhr within Europe (PURE) Ruhr University Bochum  Bochum Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Taeger","sequence":"additional","affiliation":[{"name":"Institute for Prevention and Occupational Medicine of the German Social Accident Insurance Institute of the Ruhr\u2010Universit\u00e4t Bochum (IPA)  Bochum Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Gawrych","sequence":"additional","affiliation":[{"name":"Institute for Prevention and Occupational Medicine of the German Social Accident Insurance Institute of the Ruhr\u2010Universit\u00e4t Bochum (IPA)  Bochum Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Johnen","sequence":"additional","affiliation":[{"name":"Institute for Prevention and Occupational Medicine of the German Social Accident Insurance Institute of the Ruhr\u2010Universit\u00e4t Bochum (IPA)  Bochum Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9verine","family":"Banek","sequence":"additional","affiliation":[{"name":"Institute of Urology Eberhard Karls University  T\u00fcbingen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Schwentner","sequence":"additional","affiliation":[{"name":"Institute of Urology Eberhard Karls University  T\u00fcbingen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl\u2010Dietrich","family":"Sievert","sequence":"additional","affiliation":[{"name":"Institute of Urology Eberhard Karls University  T\u00fcbingen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Wellh\u00e4u\u00dfer","sequence":"additional","affiliation":[{"name":"German Social Accident Insurance's Institution for the Raw Materials and Chemical Industry (BG RCI)  Heidelberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Kluckert","sequence":"additional","affiliation":[{"name":"German Social Accident Insurance's Institution for the Raw Materials and Chemical Industry (BG RCI)  Heidelberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Leng","sequence":"additional","affiliation":[{"name":"Department of Health Protection and Occupational Safety Currenta GmbH &amp; Co. OHG (formerly Bayer)  Leverkusen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Nasterlack","sequence":"additional","affiliation":[{"name":"Department of Occupational Medicine and Health Protection BASF SE  Ludwigshafen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnulf","family":"Stenzl","sequence":"additional","affiliation":[{"name":"Institute of Urology Eberhard Karls University  T\u00fcbingen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Behrens","sequence":"additional","affiliation":[{"name":"Institute for Prevention and Occupational Medicine of the German Social Accident Insurance Institute of the Ruhr\u2010Universit\u00e4t Bochum (IPA)  Bochum Germany"},{"name":"Protein Research Unit Ruhr within Europe (PURE) Ruhr University Bochum  Bochum Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Br\u00fcning","sequence":"additional","affiliation":[{"name":"Institute for Prevention and Occupational Medicine of the German Social Accident Insurance Institute of the Ruhr\u2010Universit\u00e4t Bochum (IPA)  Bochum Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beate","family":"Pesch","sequence":"additional","affiliation":[{"name":"Institute for Prevention and Occupational Medicine of the German Social Accident Insurance Institute of the Ruhr\u2010Universit\u00e4t Bochum (IPA)  Bochum Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"The UroScreen Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,1,25]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2008.02225.x"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05509.x"},{"key":"e_1_2_8_4_1","first-page":"412","article-title":"Urine cytology and adjunct markers for detection and surveillance of bladder cancer","volume":"2","author":"Sullivan P","year":"2010","journal-title":"Am J Transl Res"},{"key":"e_1_2_8_5_1","unstructured":"US Federal Food and Drug Administration.UroVysionTMBladder Cancer Kit \u2013 P030052.2005. Available at:http:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfTopic\/pma\/pma.cfm?num=P030052. Accessed August 2012"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1101\/pdb.top069229"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000323652"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPKKWBDSAOZ4RW"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-008-0812-0"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-008-0280-3"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10883.x"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0035363"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1271424"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09971.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2012.04.015"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/106689690501300203"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.101.2629.519"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.08.064"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.21065"},{"key":"e_1_2_8_20_1","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.5858\/2009-0731-RA.1","article-title":"UroVysion, urine cytology, and the College of American Pathologists: where should we go from here?","volume":"134","author":"Renshaw AA","year":"2010","journal-title":"Arch Pathol Lab Med"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2009.11.004"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1525-1578(10)60625-3"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1309\/K5P2-4Y8B-7L5A-FAA9"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAP.0b013e3181832320"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2007.049684"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2012.11666.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2012.11666.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T11:32:32Z","timestamp":1761737552000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2012.11666.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,25]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["10.1111\/j.1464-410X.2012.11666.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2012.11666.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"type":"print","value":"1464-4096"},{"type":"electronic","value":"1464-410X"}],"subject":[],"published":{"date-parts":[[2013,1,25]]},"assertion":[{"value":"2013-01-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}